In vivo therapeutic eVect of CDH3/P-cadherin-Targeting radioimmunotherapy

Cancer Immunology, Immunotherapy

Volumn 61, Issue 8, 2012, Pages 1211-1220

  Yoshioka, Hiroki ^a,b   Yamamoto, Shinji ^a,b   Hanaoka, Hirofumi ^a   Iida, Yasuhiko ^a   Paudyal, Pramila ^a   Higuchi, Tetsuya ^a   Tominaga, Hideyuki ^a   Oriuchi, Noboru ^a   Nakagawa, Hidewaki ^c   Shiba, Yasuhiro ^b   Yoshida, Koji ^a,b   Osawa, Ryuji ^b   Katagiri, Toyomasa ^b,d   Tsunoda, Takuya ^b   Nakamura, Yusuke ^e   Endo, Keigo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Research and Development Division   (Japan)

^c RIKEN   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

CDH3 P cadherin; Colorectal cancer; Lung cancer; Radioimmunotherapy; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; INDIUM 111; P CADHERIN; UNCLASSIFIED DRUG; YTTRIUM MONOCLONAL ANTIBODY 6 Y 90; CADHERIN; MONOCLONAL ANTIBODY; YTTRIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG LABELING; DRUG SAFETY; FEMALE; GENETIC IMMUNIZATION; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; TOXICITY TESTING; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG SCREENING; FLOW CYTOMETRY; LUNG TUMOR; METHODOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CADHERINS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; RADIOIMMUNOTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 84865775005     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1186-0     Document Type: Article

References (31)

1. Maloney DG, Grillo-López AJ, White CA et al (1997) IDECC2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195 (Pubitemid 27392702)
2. McNeil C (1998) Herceptin raises its sights beyond advanced breast cancer. J Natl Cancer Inst 90:882-883 (Pubitemid 28304154)
3. Chen HX, Gore-Langton RE, Cheson BD (2001) Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Williston Park) 15:1017, 1020, 1023-1026
4. Baselga J (2001) The EGFR as a target for anticancer therapyfocus on cetuximab. Eur J Cancer 37(Suppl 4):S16-S22 (Pubitemid 32938125)
5. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863-878
6. Palanca-Wessels MC, Press OW (2010) Improving the eYcacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer 116:1126-1133
7. Jain M, Venkatraman G, Batra SK (2007) Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res 13:1374-1382 (Pubitemid 46450425)
8. Bischof DA (2003) The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL). Leuk Lymphoma 44(Suppl 4):S29-S36
9. Chinn P, Braslawsky G, White C, Hanna N (2003) Antibody therapy of non-Hodgkin's B-cell lymphoma. Cancer Immunol Immunother 52:257-280 (Pubitemid 36581906)
10. Nakamura T, Furukawa Y, Nakagawa H et al (2004) Genomewide cDNA microarray analysis of gene expression proWles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 23:2385-2400 (Pubitemid 38496794)
11. Hasegawa S, Furukawa Y, Li M et al (2002) Genome-wide analysis of gene expression in intestinal-Type gastric cancers using a complementary DNA microarray representing 23, 040 genes. Cancer Res 62:7012-7017 (Pubitemid 35424095)
12. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y (2002) Molecular diagnosis of colorectal tumors by expression proWles of 50 genes expressed diVerentially in adenomas and carcinomas. Oncogene 21:4120-4128 (Pubitemid 34712879)
13. Kikuchi T, Daigo Y, Katagiri T et al (2003) Expression proWles of non-small cell lung cancers on cDNA microarrays: identiWcation of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22:2192-2205 (Pubitemid 36539569)
14. Takata R, Katagiri T, Kanehira M et al (2005) Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression proWling. Clin Cancer Res 11:2625-2636 (Pubitemid 40569463)
15. Imai K, Hirata S, Irie A et al (2008) IdentiWcation of a novel tumor-Associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 14:6487-6495
16. Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC (2007) P-cadherin expression in breast cancer: A review. Breast Cancer Res 9:214
17. Taniuchi K, Nakagawa H, Hosokawa M et al (2005) Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res 65:3092-3099 (Pubitemid 40524589)
18. Tang DC, De Vit M, Johnston SA (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356:152-154
19. Fukukawa C, Hanaoka H, Nagayama S et al (2008) Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci 99:432-440 (Pubitemid 351228502)
20. Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR (1999) Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 15:1017-1025
21. Wheelock MJ, Johnson KR (2003) Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 19:207-235 (Pubitemid 37487348)
22. Takeichi M (1988) The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development 102:639-655
23. Nose A, Takeichi M (1986) A novel cadherin cell adhesion molecule: its expression patterns associated with implantation and organogenesis of mouse embryos. J Cell Biol 103:2649-2658 (Pubitemid 17008011)
24. Jain RK, Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: signiWcance of elevated interstitial pressure. Cancer Res 48:7022-7032 (Pubitemid 19013976)
25. Motta-Hennessy C, Sharkey RM, Goldenberg DM (1990) Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse. J Nucl Med 31:1510-1519 (Pubitemid 20293687)
26. Duncan JR, Welch MJ (1993) Intracellular metabolism of indium- 111-DTPA-labeled receptor targeted proteins. J Nucl Med 34: 1728-1738 (Pubitemid 23295386)
27. Franano FN, Edwards WB, Welch MJ, Duncan JR (1994) Metabolism of receptor targeted 111In-DTPA-glycoproteins: identiWcation of 111In-DTPA-epsilon-lysine as the primary metabolic and excretory product. Nucl Med Biol 21:1023-1034
28. Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L et al (1997) Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer 29:477-485 (Pubitemid 27325876)
29. Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C et al (1999) Studies on the red marrow dosimetry in radioimmunotherapy: An experimental investigation of factors inXuencing the radiation- induced myelotoxicity in therapy with α-, auger/conversion electron-, or α-emitters. Clin Cancer Res 5:3031s-3043s (Pubitemid 29493892)
30. Esteban JM, Hyams DM, Beatty BG, Merchant B, Beatty JD (1990) Radioimmunotherapy of human colon carcinomatosis xenograft with 90Y-ZCE025 monoclonal antibody: toxicity and tumor phenotype studies. Cancer Res 50:989s-992s (Pubitemid 20054254)
31. Zhang CC, Yan Z, Zhang Q et al (2010) PF-03732010: A fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. Clin Cancer Res 16:5177-5188